Skip to main content
Clinical Trials/NCT05443672
NCT05443672
Unknown
Not Applicable

A Multi-center Study of Breast Mass Screening and Diagnosis Using Deep Learning AI-based on Real-time Ultrasound Examination

Cancer Institute and Hospital, Chinese Academy of Medical Sciences1 site in 1 country1,122 target enrollmentAugust 12, 2021

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Breast Neoplasms
Sponsor
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Enrollment
1122
Locations
1
Primary Endpoint
Diagnostic performance of breast mass using deep learning AI-based real-time ultrasound examination
Last Updated
3 years ago

Overview

Brief Summary

This multi-center study intends to evaluate the value of the detection and differential diagnosis of breast mass using deep learning AI-based real-time ultrasound examination.

Detailed Description

As the most common cancer expected to occur all over the world, extensive population screening plays a very important role in the early diagnosis and prognosis of the breast cancer. X-ray and ultrasound are the most commonly used screening methods, and ultrasound is especially important for Asian women with dense breasts. However, ultrasound is greatly affected by the operator's skill and experience, and the diagnostic accuracy varies greatly. Artificial intelligence (AI) is a new method emerging in recent years, active in many medical fields and can effectively improve the diagnostic efficiency. However, previous researches on the application of AI in ultrasound are focused on single or multi-modality static ultrasound images. This multi-center study intends to evaluate the value of the detection and differential diagnosis of breast mass using deep learning AI-based real-time ultrasound examination.

Registry
clinicaltrials.gov
Start Date
August 12, 2021
End Date
August 31, 2023
Last Updated
3 years ago
Study Type
Observational
Sex
Female

Investigators

Eligibility Criteria

Inclusion Criteria

  • Females who undergo ultrasound examination for a complaint of breast lesion;
  • The breast lesion that will obtain definite pathological diagnosis or follow-up at least two years.

Exclusion Criteria

  • The breast lesion that has received CNB or FNA;
  • The breast cancer patient who has received neoadjuvant chemotherapy.

Outcomes

Primary Outcomes

Diagnostic performance of breast mass using deep learning AI-based real-time ultrasound examination

Time Frame: 12 months

Pathology as a gold standard, to evaluate the diagnostic performance (sensitivity, specificity and accuracy)

Study Sites (1)

Loading locations...

Similar Trials